Imaging Diagnostic Systems (IMDS) Signs Collaborative Agreement With The Rumbaugh-Goodwin Institute for Cancer Research, In 
10/19/2005 5:10:17 PM

FORT LAUDERDALE, Fla., Nov. 5 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc. (BULLETIN BOARD: IMDS) announced today the signing of a collaborative agreement with the Rumbaugh-Goodwin Institute for Cancer Research, Inc. ( for the development of optical imaging products for the laboratory market.

Linda Grable, CEO, stated, "With this agreement, IDSI is addressing a new market, targeting pharmaceutical developers and researchers who monitor cancer growth. It is exciting and beneficial to be adding a new product line to complement our CTLM(R) breast imaging product. This work draws on the nine years of R&D at Imaging Diagnostics in the optical imaging field, particularly drawing on the fluorescence work we have done at the University of Virginia and the cooperative work with Schering AG."

Robert Wake, Vice President of Engineering, stated, "An extension of IDSI's optical computed tomography and fluorescent imaging technologies is the development of a new product line: Laser Imaging for Lab Animals (LILA)(TM). The first model of the LILA(TM) product line is a miniature optical CT scanner for imaging green fluorescent protein, derived from the DNA of jellyfish. This product is addressing a new market, targeting pharmaceutical developers and researchers who use optical imaging in their clinical research. The scanner is the first of a series of optical imaging products for the research laboratory."

Dr. Alex Aller, Director of RGI, said, "The LILA will provide a powerful tool for scientists to monitor cancer growth, metastasis (spread) and the effect of new therapies in the treatment of cancer."

The Rumbaugh-Goodwin Institute for Cancer Research, Inc. brings to this collaboration their expertise in optical imaging for determining efficacy of new anti-cancer treatments and spontaneously metastasizing models of human breast cancer. The Institute's main goal is to develop cancer therapies targeting tumors, with minimal cellular damage and toxicity to the patient. Its long-standing relationship with the National Cancer Institute (NCI) and the National Institutes of Health (NIH) provides support for the advancement and development of these kinds of promising new investigational therapies.

Imaging Diagnostic Systems has received CE Marketing, UL Listing, ISO 9001:2000 certification and FDA export certification for its CT Laser Breast imaging systems. The CTLM(R) system is the first patented breast-imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLM(R) system to be used as an adjunct to mammography. The CTLM(R) system is a non-invasive, painless examination that does not expose the patient to radiation nor require breast compression.

Please visit Imaging Diagnostic Systems' website at: for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of the future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filing with the Securities Exchange Commission.

Investor Relations: Rick Lutz 404-261-1196 Public Relations: Margie Adelman

Imaging Diagnostic Systems, Inc.

CONTACT: Investors, Rick Lutz, +1-404-261-1196,; or Margie Adelman,,both for Imaging Diagnostic Systems, Inc.